统一GFR估算方法:NKF-ASN工作组关于重新评估种族纳入肾脏病诊断的建议
NKF与ASN工作组用10个月评估26种GFR估算方法后聚焦5种,从6个维度评判,建议美国实验室立即采用不含种族的CKD-EPI肌酐方程,并推动胱抑素C常规使用以联合肌酐确认eGFR。
要点
- 美国成人推荐立即采用不含种族的CKD-EPI肌酐方程。
- 应推动胱抑素C常规使用,联合肌酐可提高eGFR准确性。
- 鼓励研究新内源性滤过标志物及消除种族差异的干预。
核心结论
- 美国成人应统一采用不含种族的CKD-EPI肌酐方程估算GFR,并推动胱抑素C常规使用以联合肌酐确认。
研究设计与样本
- NKF与ASN成立工作组,10个月内分阶段评估26种GFR估算方法,共识聚焦5种,从6个维度综合评价。
主要发现
- 工作组从26种方法中经共识聚焦5种,从6个属性整体评估各方法优劣。
关键数值与推荐
- 推荐美国所有实验室立即实施不含种族变量的CKD-EPI肌酐方程重拟合版。
- 推荐国家层面推动胱抑素C更频繁、常规和及时使用,尤其用于确认高危或CKD成人的eGFR。
- 若持续证据支持可接受性能,应采用不含种族的CKD-EPI eGFRcys和eGFRcr-cys_R重拟合版作为一线检测。
- 鼓励并资助新内源性滤过标志物及消除种族和民族差异干预的研究。
临床怎么用
- 美国实验室应统一采用不含种族的CKD-EPI肌酐方程报告eGFR。
- 对CKD高危或已患病成人,应联合肌酐和胱抑素C确认eGFR。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In response to a national call for re-evaluation of the use of race in clinical algorithms, the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) established a Task Force to reassess inclusion of race in the estimation of glomerular filtration rate (GFR) in the United States and its implications for diagnosis and management of patients with, or at risk for, kidney diseases. PROCESS & DELIBERATIONS: The Task Force organized its activities over 10 months in phases to (1) clarify the problem and evidence regarding GFR estimating equations in the United States (described previously in an interim report), and, in this final report, (2) evaluate approaches to address use of race in GFR estimation, and (3) provide recommendations. We identified 26 approaches for the estimation of GFR that did or did not consider race and narrowed our focus, by consensus, to 5 of those approaches. We holistically evaluated each approach considering 6 attributes: assay availability and standardization; implementation; population diversity in equation development; performance compared with measured GFR; consequences to clinical care, population tracking, and research; and patient centeredness. To arrive at a unifying approach to estimate GFR, we integrated information and evidence from many sources in assessing strengths and weaknesses in attributes for each approach, recognizing the number of Black and non-Black adults affected. RECOMMENDATIONS: (1) For US adults (>85% of whom have normal kidney function), we recommend immediate implementation of the CKD-EPI creatinine equation refit without the race variable in all laboratories in the United States because it does not include race in the calculation and reporting, included diversity in its development, is immediately available to all laboratories in the United States, and has acceptable performance characteristics and potential consequences that do not disproportionately affect any one group of individuals. (2) We recommend national efforts to facilitate increased, routine, and timely use of cystatin C, especially to confirm estimated GFR in adults who are at risk for or have chronic kidney disease, because combining filtration markers (creatinine and cystatin C) is more accurate and would support better clinical decisions than either marker alone. If ongoing evidence supports acceptable performance, the CKD-EPI eGFR-cystatin C (eGFRcys) and eGFR creatinine-cystatin C (eGFRcr-cys_R) refit without the race variables should be adopted to provide another first-line test, in addition to confirmatory testing. (3) Research on GFR estimation with new endogenous filtration markers and on interventions to eliminate race and ethnic disparities should be encouraged and funded. An investment in science is needed for newer approaches that generate accurate, unbiased, and precise GFR measurement and estimation without the inclusion of race, and that promote health equity and do not generate disparate care. IMPLEMENTATION: This unified approach, without specification of race, should be adopted across the United States. High-priority and multistakeholder efforts should implement this solution.
引用
- Delgado C, Baweja M, Crews DC, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Am J Kidney Dis. 2021. PMID: 34563581. doi:10.1053/j.ajkd.2021.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。